Long term cryopreservation in 5% DMSO maintains unchanged CD34(+) cells viability and allows satisfactory hematological engraftment after peripheral blood stem cell transplantation

Vox Sang. 2013 Jul;105(1):77-80. doi: 10.1111/vox.12012. Epub 2013 Feb 6.

Abstract

Peripheral blood stem cell cryopreservation is associated with cell damage and decreased viability. We evaluated the impact of up to 10 years of cryopreservation (5% DMSO) on viability of CD34(+) cells utilizing graft samples of consecutive patients (2002-2012) with different malignancies who underwent stem cell collection and transplantation. Viability of CD34(+) cells from oncohaematological patients measured after 5 weeks (97·2 ± 0·6%) or after 9-10 years of cryopreservation (95·9 ± 0·5%) was unaffected. Haemoglobin, granulocyte and platelet recovery after transplantation of long-term cryopreserved grafts occurred within 8-13 days. CD34(+) stem cells can be safely stored up to 9-10 years, without affecting cell viability and clinical effectiveness.

Publication types

  • Clinical Trial

MeSH terms

  • Allografts
  • Cell Survival
  • Cryopreservation*
  • Cryoprotective Agents / pharmacology*
  • Dimethyl Sulfoxide / pharmacology*
  • Female
  • Graft Survival*
  • Hematopoietic Stem Cells*
  • Humans
  • Male
  • Neoplasms / therapy*
  • Peripheral Blood Stem Cell Transplantation*
  • Time Factors

Substances

  • Cryoprotective Agents
  • Dimethyl Sulfoxide